Yang Jie, Zhu Yunyun, Zhou Yijian, Zhang Jiaying, Wei Yuxuan, Liu Yongpan, Zhang Bo, Xie Jialing, An Xiaolu, Qi Xianhua, Yue Yuting, Zhang Lijia, Zhang Xiajun, Fu Zhichao, Liu Kuancan
Central Laboratory, Danyang People's Hospital of Jiangsu Province, Danyang, Jiangsu, 212300, P.R. China.
Department of Radiotherapy, 900 Hospital of the Joint Logistics Team, (Dongfang Hospital, Xiamen University), Fuzhou, Fujian, 350025, P.R. China.
BMC Cancer. 2025 Mar 11;25(1):438. doi: 10.1186/s12885-025-13866-x.
Esophageal squamous cell carcinoma (ESCC), the most common type of esophageal cancer, characterized by low five-year survival rate, and concurrent chemoradiotherapy (CCRT) has been proposed to treat ESCC, while potential biomarkers for prognostic monitoring after optimized CCRT remains unknown.
Serum samples from 45 patients with ESCC were collected and categorized into three groups: Control (pre-CCRT), CCRT (during CCRT), and CCRT-1 M (one-month post-CCRT). The therapeutic effect was evaluated using CT imaging and established evaluation criteria. Untargeted metabolomic analysis was performed on the serum samples to identify differential metabolites caused by CCRT treatment, assessing their potential for prognostic monitoring.
CCRT had significant therapeutic efficacy in patients with ESCC, as indicated by CT imaging and RECIST 1.1 solid tumor evaluation criteria. Notably, several metabolic markers were identified through non-targeted metabolomic analysis, highlighting changes following CCRT treatment. These differential metabolites are involved in the dysregulation of phenylalanine, tyrosine, and tryptophan biosynthesis, as well as histidine, arginine, and proline metabolism, and glycine, serine, and threonine metabolism, suggesting a reduction in glucose metabolism in patients with ESCC after CCRT. Additionally, ROC analysis indicated that the AUC of these metabolites exceeded 0.661, underscoring their diagnostic value for assessing CCRT efficacy and their potential use in prognostic monitoring. Comparative metabolomic analysis identified L-phenylalanine and lysine as promising serum biomarkers for predicting therapeutic outcomes.
CCRT shows considerable therapeutic benefit in patients with ESCC, with observed reductions in glucose metabolism post-treatment. L-phenylalanine and lysine may serve as potential serum biomarkers to predict CCRT efficacy.
食管鳞状细胞癌（ESCC）是食管癌最常见的类型，其五年生存率较低，同步放化疗（CCRT）已被提议用于治疗ESCC，而优化CCRT后用于预后监测的潜在生物标志物仍不明确。
收集45例ESCC患者的血清样本，并分为三组：对照组（CCRT前）、CCRT组（CCRT期间）和CCRT-1M组（CCRT后1个月）。使用CT成像和既定评估标准评估治疗效果。对血清样本进行非靶向代谢组学分析，以鉴定由CCRT治疗引起的差异代谢物，评估其预后监测潜力。
CT成像和RECIST 1.1实体瘤评估标准表明，CCRT对ESCC患者具有显著的治疗效果。值得注意的是，通过非靶向代谢组学分析鉴定出了几种代谢标志物，突出了CCRT治疗后的变化。这些差异代谢物参与苯丙氨酸、酪氨酸和色氨酸生物合成的失调，以及组氨酸、精氨酸和脯氨酸代谢，以及甘氨酸、丝氨酸和苏氨酸代谢，表明CCRT后ESCC患者的葡萄糖代谢减少。此外，ROC分析表明，这些代谢物的AUC超过0.661，强调了它们在评估CCRT疗效方面的诊断价值及其在预后监测中的潜在用途。比较代谢组学分析确定L-苯丙氨酸和赖氨酸是预测治疗结果的有前景的血清生物标志物。
CCRT对ESCC患者显示出相当大的治疗益处，治疗后观察到葡萄糖代谢减少。L-苯丙氨酸和赖氨酸可能作为预测CCRT疗效的潜在血清生物标志物。
